New drug cocktail aims to tame stubborn IBD
NCT ID NCT07487311
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining guselkumab with JAK inhibitors (upadacitinib or tofacitinib) can help people with inflammatory bowel disease that hasn't improved with other treatments. About 80 participants will receive the drug combination and be monitored for 12 and 52 weeks to see if their symptoms and gut inflammation improve. The goal is to find a new option for those with limited choices.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
guselkumab and JAK inhibitors (upadacitinib or tofacitinib)
What this could lead to
If it works, this combination could offer a new treatment option for people with inflammatory bowel disease that hasn't responded to other therapies.
What could go wrong
This is a small, early-phase study with only 80 participants, so results may not apply to everyone. Combining two strong drugs also raises the risk of side effects like infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMATORY BOWEL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Center of Inflammatory Bowel Disease, Department of Gastroenterology, the Second Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••